Data from Pharmawand - Curated by Toby Galbraith - Date added 11 September 2017

Eisai announced a delay in the deterioration of five health-related quality of life domains that affect patients' daily lives was observed in patients treated with Lenvima (lenvatinib) as compared to those treated with sorafenib in the Phase III REFLECT study evaluating lenvatinib compared to sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Quality of life scores declined with both treatments over the course of the study.

The secondary endpoint of HRQOL was assessed using the EORTC QLQ-C30 questionnaire and the HCC-specific module (EORTC QLQ-HCC18). Treatment with lenvatinib resulted in a longer median time to delay in worsening in the QLQ-C30 domains of role function (2.0 months vs 1.9 months; nominal p=0.0098), pain (2.0 months vs 1.8 months; nominal p=0.006) and diarrhea (4.6 months vs 2.7 months; nominal p<0.0001), and in the QLQ-HCC18 domains of body image (2.8 months vs 1.9 months; nominal p=0.0041) and nutrition (4.1 months vs 2.8 months; nominal p=0.006). There were no nominally significant differences in the other domains of the two scales (QLQ-C30 and QLQ-HCC18). Baseline HRQOL scores were similar for patients receiving either treatment across all domains. These data were presented at the European Society of Medical Oncology (ESMO) 2017 Congress.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Visit Oral Anticoagulation Reversal

Related Content